Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

27.03 +0.29 (+1.08%)
Streaming Delayed Price Updated: 12:27 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
One of them is performing much better than the other this year. 
Via The Motley Fool
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
How long will the momentum last? 
Via The Motley Fool
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via AB Newswire
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
 
Via Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
 
Via Benzinga
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge. 
Via News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study. 
Via The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
There's a lot of hope for ivonescimab, but are investors being a bit too bullish? 
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
Via Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
From Summit Therapeutics Inc.
Via Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
Via Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy. 
Via The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers. 
Via The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
This high-flying biotech stock is moving even higher -- and for good reason. 
Via The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
The company is adding onto its success outperforming Merck's top drug in lung cancer patients. 
Via Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab. 
Via MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net proceeds. 
Via Benzinga
Summit Therapeutics Raises $235 Million
From Summit Therapeutics Inc.
Via Business Wire
Is Summit Therapeutics a Buy Now?
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug. 
Via The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market. 
Via The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%. 
Via Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.